Combination of molecularly-targeted therapy with stereotactic body radiotherapy in hepatocellular carcinoma with major vascular invasio
Not Applicable
Recruiting
- Conditions
- Hepatocellular carcinoma with major vascular invasion
- Registration Number
- JPRN-UMIN000030718
- Lead Sponsor
- Osaka International Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
The subject must be excluded if the subject; 1) Has the hepatic encephalopathy 2) Has the uncontrollable hypertension, heart failure, ischemic heart disease or arrhythmia. 3) Has had the acute myocardial infarction in the last 6 months. 4) Has the synchronous malignancies of other organs, or has had the metachronous ones in the last 2 years. 5) Has the serious psychiatric disorder or a serious decline in cognitive function. 6) Is pregnant or breastfeeding, or a female expecting to conceive a child. 7) Is judged to be inappropriate for the entry of this trial in the opinion of the treating investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety; occurrence rate of adverse events, occurrence rate of adverse events of grade 3 or more.
- Secondary Outcome Measures
Name Time Method Efficacy; overall survival rate, progression-free survival, response rate, disease control rate